NICE publishes final appraisal document on olaparib with bevacizumab for maintenance treatment of advanced high-grade ovarian, fallopian tube or primary peritoneal cancer

In DRAFT guidance, NICE recommends its use within the Cancer Drugs Fund for maintenance treatment in adults who have had a complete or partial response after 1st-line platinum-based chemotherapy and bevacizumab, if the cancer is associated with homologous recombination deficiency

National Institute for Health and Care Excellence